By passing SB 914, Michigan will join 26 other states, the District of Columbia, and Puerto Rico in protecting consumers purchasing insurance on the private market. This legislation ensures that copay assistance counts toward cost-sharing obligations, preventing patients from facing insurmountable financial barriers to their medications.
While we share your commitment to addressing the high cost of prescription drugs, we strongly oppose HB 1236, legislation that would explicitly authorize the use of copay maximizer programs in Louisiana’s health insurance market.
We strongly support the Department of Labor’s proposed rule to increase transparency in pharmacy benefit manager (PBM) compensation and financial arrangements. Greater transparency is essential to improving accountability across the prescription drug supply chain and ensuring that plan fiduciaries have the information necessary to assess the reasonableness of PBM contracts and practices. We urge the Department to finalize and implement this rule without delay, with the recommendations outlined in this letter.
We urge CMS to prioritize oversight of the Marketplace, which serves as an essential safety net within the country’s health insurance system and is of critical importance to people affected by HIV and other serious and chronic health conditions. We urge CCIIO to reject proposals that decrease access to care by weakening network adequacy, time and distance, and ECP standards; enforce existing rules requiring copay assistance to count towards patient cost-sharing and that covered drugs are considered EHB; and improve the tools CMS provides to regulators to detect formulary coverage that deters enrollment by people living with HIV. As the key regulator of health insurance in the United States, we urge CCIIO to ensure that Marketplace plans provide meaningful, affordable, and non-discriminatory coverage to all.
By passing SB 1199, California will join 26 other states, the District of Columbia, and Puerto Rico in protecting consumers purchasing insurance on the private market. This legislation ensures that copay assistance counts toward cost-sharing obligations, preventing patients from facing insurmountable financial barriers to their medications.